The innovative drug concept continues its recent gains. As of press release, Lepu Bio-B (02157) rose 7.23% to HK$4.45; Pharmacology Juno-B (02126) rose 5.98% to HK$2.48; Clover Bio-B (02197) rose 5.63% to HK$0.75; and Genting Xinyao B (01952) rose 3.99% to HK$30.
The Zhitong Finance App learned that the innovative drug concept continued its recent gains. As of press release, Lepu Biotech B (02157) rose 7.23% to HK$4.45; Pharmacology Juno-B (02126) rose 5.98% to HK$2.48; Clover Biotech B (02197) rose 5.63% to HK$0.75; and Genting Xinyao B (01952) rose 3.99% to HK$30.
According to the news, recently, at the “15th China Pharmaceutical Entrepreneurs, Scientists and Investors Conference”, Weng Linjia, Deputy Director of the Pharmaceutical Prices and Bidding and Procurement Department of the National Medical Security Administration, revealed during a keynote speech that the National Health Insurance Administration is adjusting the pricing policy for innovative drugs and is adopting relatively relaxed management of prices in the early stages of marketing of innovative drugs on the basis of the “Guidelines for the Formation of Prices for COVID-19 Therapeutics”.
According to the report, industry insiders affirm the positive guiding effect of this signal and believe that the innovative drug price protection mechanism is more likely to be implemented, which is a true reflection of further deepening the reform of the pharmaceutical system and can bring “a ray of sunshine” to the current pharmaceutical winter period.